Failure of a company's lead product candidate in clinical trials is often catastrophic for existing shareholders of a development phase pharmaceutical company. I have first-hand experience with significant losses from multiple investments over the last decade in which I had foolishly held large holdings through such binary events believing that positive news or FDA approval was imminent. While existing shareholders may often be hard-pressed to recoup their losses for quite some time, I believe the oversold condition in these companies' common shares created by these lead-candidate failures can create potentially-lucrative entries for new shareholders with the foresight and knowledge to see past such disappointments.
Only subscribers can access this article, which is part of the PRO research library covering 3,558 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: